Allison Norvil

Ms. Allison Norvil


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2016 in Nature Communications
Verified
Journal Article
Open access
KSKatherine E. Savell
Katherine E. Savell
NGNancy V. N. Gallus
Nancy V. N. Gallus
RSRhiana C. Simon
Rhiana C. Simon
JBJordan A. Brown
Jordan A. Brown
JRJasmin S. Revanna
Jasmin S. Revanna
JDJeremy Day
Jeremy Day
Epigenetic mechanisms such as DNA methylation are essential regulators of the function and information storage capacity of neurons. DNA methylation is highly dynamic in the developing and adult brain, and is actively regulated by neuronal activity and behavioural experiences. However, it is presently unclear how methylation status at individual genes is targeted for modification. Here, we report that extra-coding RNAs (ecRNAs) interact with DNA methyltransferases and regulate neuronal DNA methylation. Expression of ecRNA species is associated with gene promoter hypomethylation, is altered by neuronal activity, and is overrepresented at genes involved in neuronal function. Knockdown of the Fos ecRNA locus results in gene hypermethylation and mRNA silencing, and hippocampal expression of Fos ecRNA is required for long-term fear memory formation in rats. These results suggest that ecRNAs are fundamental regulators of DNA methylation patterns in neuronal systems, and reveal a promising avenue for therapeutic targeting in neuropsychiatric disease states.

1 August 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AHAli Hammad
Ali Hammad
NANader S. Abutaleb
Nader S. Abutaleb
MEMohamed Mustafa Mustafa Elnagar
Mohamed Mustafa Mustafa Elnagar
ANAllison Norvil
Allison Norvil
MAMohamed Alswah
Mohamed Alswah
AMAbdelrahman S. Mayhoub
Abdelrahman S. Mayhoub

29 April 2021 in Blood
Verified
Journal Article
Closed access
PDF file
TKTasneem Khanam
Tasneem Khanam
SSSarah Sandmann
Sarah Sandmann
JSJochen Seggewiss
Jochen Seggewiss
CRCharlotte Marie Ruether
Charlotte Marie Ruether
MZMartin Zimmermann
Martin Zimmermann
HHHeidrun Herbrüggen
Heidrun Herbrüggen
T-cell lymphoblastic lymphoma (T-LBL) is a heterogeneous malignancy of lymphoblasts committed to T-cell lineage. Dismal outcomes (15-30%) in case of T-LBL relapses warrants for establishing risk-based treatment in future. This is a first comprehensive, systematic, integrated genome-wide analysis including relapse cases aimed towards identifying molecular markers of prognostic relevance for T-LBL. NOTCH1 was identified as putative driver for T-LBL. Activated NOTCH/PI3K-AKT signaling axis and alterations in cell cycle regulators constitutes the core oncogenic program for T-LBL. Mutated KMT2D was identified as a prognostic marker. The cumulative incidence of relapse was 47±17% in patients with KMT2D mutations compared with 14±3% in KMT2D wildtype. Structural analysis of the mutated domains of KMT2D revealed plausible impact on the structure and functional consequences. These findings provide new insights into the pathogenesis of T-LBL including high translational potential. The ongoing trial LBL 2018 (NCT04043494) allows prospective validation and subsequent fine-tuning of the stratification criteria for T-LBL risk groups to improve survival of the pediatric patients.

1 December 2021 in NAR Cancer
Verified
Journal Article
Open access
PDF file
IMIsaiah K Mensah
Isaiah K Mensah
ANAllison Norvil
Allison Norvil
LALama AlAbdi
Lama AlAbdi
SMSarah McGovern
Sarah McGovern
CPChristopher J Petell
Christopher J Petell
Humaira GowherHumaira Gowher
Humaira Gowher
In mammals, DNA methyltransferases DNMT1 and DNMT3’s (A, B and L) deposit and maintain DNA methylation in dividing and nondividing cells. Although these enzymes have an unremarkable DNA sequence specificity (CpG), their regional specificity is regulated by interactions with various protein factors, chromatin modifiers, and post-translational modifications of histones. Changes in the DNMT expression or interacting partners affect DNA methylation patterns. Consequently, the acquired gene expression may increase the proliferative potential of cells, often concomitant with loss of cell identity as found in cancer. Aberrant DNA methylation, including hypermethylation and hypomethylation at various genomic regions, therefore, is a hallmark of most cancers. Additionally, somatic mutations in DNMTs that affect catalytic activity were mapped in Acute Myeloid Leukemia cancer cells. Despite being very effective in some cancers, the clinically approved DNMT inhibitors lack specificity, which could result in a wide range of deleterious effects. Elucidating distinct molecular mechanisms of DNMTs will facilitate the discovery of alternative cancer therapeutic targets. This review is focused on: (i) the structure and characteristics of DNMTs, (ii) the prevalence of mutations and abnormal expression of DNMTs in cancer, (iii) factors that mediate their abnormal expression and (iv) the effect of anomalous DNMT-complexes in cancer.

1 July 2018 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
LALama AlAbdi
Lama AlAbdi
MHMing He
Ming He
QYQianyi Yang
Qianyi Yang
ANAllison Norvil
Allison Norvil
Humaira GowherHumaira Gowher
Humaira Gowher
Formation of the vasculature by angiogenesis is critical for proper development, but angiogenesis also contributes to the pathogenesis of various disorders, including cancer and cardiovascular diseases. Vascular endothelial zinc finger 1 (Vezf1), is a Krüppel-like zinc finger protein that plays a vital role in vascular development. However, the mechanism by which Vezf1 regulates this process is not fully understood. Here, we show that Vezf1−/− mouse embryonic stem cells (ESC) have significantly increased expression of a stem cell factor, Cbp/p300-interacting transactivator 2 (Cited2). Compared with WT ESCs, Vezf1−/− ESCs inefficiently differentiated into endothelial cells (ECs), which exhibited defects in the tube-formation assay. These defects were due to reduced activation of EC-specific genes concomitant with lower enrichment of histone 3 acetylation at Lys27 (H3K27) at their promoters. We hypothesized that overexpression of Cited2 in Vezf1−/− cells sequesters P300/CBP away from the promoters of proangiogenic genes and thereby contributes to defective angiogenesis in these cells. This idea was supported by the observation that shRNA-mediated depletion of Cited2 significantly reduces the angiogenic defects in the Vezf1−/− ECs. In contrast to previous studies that have focused on the role of Vezf1 as a transcriptional activator of proangiogenic genes, our findings have revealed a role for Vezf1 in modulating the expression of the antiangiogenic factor Cited2. Vezf1 previously has been characterized as an insulator protein, and our results now provide insights into the mechanism, indicating that Vezf1 can block inappropriate, nonspecific interactions of promoters with cis-located enhancers, preventing aberrant promoter activation.

1 August 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MEMohamed Mustafa Mustafa Elnagar
Mohamed Mustafa Mustafa Elnagar
HMHaroon Mohammad
Haroon Mohammad
ASAmgad Samir
Amgad Samir
NANader S. Abutaleb
Nader S. Abutaleb
ANAllison Norvil
Allison Norvil
AMAbdelrahman S. Mayhoub
Abdelrahman S. Mayhoub